A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer
S1216 has met its accrual goal and is permanently closed to accrual effective July 15, 2017 at 11:59 p.m. Pacific.
